Grifols (GRFS) FCF Payout Ratio Growth (1y) (2011 - 2020)
Grifols (GRFS) FCF Payout Ratio Growth (1y) (2011 - 2020) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -59.92% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 65.46% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -41.69% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 31.57% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 19.88% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -41.72% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -78.31% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 498.33% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 276.00% |
| Dec 31, 2019 | 64.01% |
| Mar 31, 2019 | -137.66% |
| Dec 31, 2018 | -0.33% |
| Jun 30, 2018 | -129.46% |
| Mar 31, 2018 | 80.06% |
| Dec 31, 2017 | -16.70% |
| Dec 31, 2016 | 345.03% |
| Dec 31, 2015 | 261.03% |
| Jun 30, 2015 | -156.71% |
| Mar 31, 2015 | 326.40% |
| Dec 31, 2014 | 2,415,737.96% |
| Sep 30, 2014 | 912,292.17% |
| Jun 30, 2014 | 408.52% |
| Mar 31, 2014 | 25.06% |
| Jun 30, 2013 | -231,633.12% |
| Mar 31, 2013 | 112.08% |
| Jun 30, 2012 | 99.99% |
| Mar 31, 2012 | -49.81% |
| Sep 30, 2011 | -597.64% |